Article
Dr. Frydenberg discusses MRI’s potential as a screening tool
Mark Frydenberg, MD, of Australia's Monash University, discusses whether multiparametric MRI is ready to be used as a screening modality for prostate cancer.
Is multiparametric MRI at a point where urologists could use it as a screening modality for prostate cancer? In this interview, Mark Frydenberg, MD, of Monash University in Melbourne, Victoria, Australia, addresses this question and how the use of MRI is changing.
Also see - PET use in prostate cancer widens, but questions remain: An interview with Mark Frydenberg, MD
Related Videos
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
Related Content
